Rapport Therapeutics

RAPP

Market cap $1.89B

BOSTON and SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in two upcoming investor conferences. Jefferies Global Healthcare Conference (New York City) – fireside chat on Wednesday, June 3, 2026, at 8:45 am ET.

Rapport Therapeutics, Inc. (RAPP) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.68 per share a year ago.

Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12  RAP-219 Phase 2 trial in bipolar mania topline results now expected in the fourth quarter of 2026, ahead of previous 1H 2027 guidance RAP-219 Phase 3 program in FOS remains on track for initiation in the second quarter of 2026 Pipeline programs, including RAP-219 long-acting injectable formulation, RAP-219 in primary generalized tonic-clonic seizures, and α6β4 nAChR in chronic pain and migraine, continue to advance Strategic collaboration and license agreement entered into with Tenacia Biotechnology to develop and commercialize RAP-219 in Greater China across indications Ended the first quarter of 2026 with $476.8 million in cash, cash equivalents and short-term investments, excluding restricted cash, expected to fund operations into the second half of 2029 BOSTON and SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the quarter ending March 31, 2026, and provided a business update. “We entered 2026 with strong momentum across the RAP-219 development program, highlighted by compelling new follow-up Phase 2a data recently presented at AAN that further reinforces RAP-219's treatment effect in focal onset seizures and builds confidence as we enter our Phase 3 trials,” said Abraham N.

MODALITES DE MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025 La société AdVini annonce avoir mis à la disposition du public et déposé auprès de l'Autorité des Marchés Financiers son Rapport Financier Annuel 2025.Le Rapport Financier Annuel peut être consulté sur le site internet de la société à l'adresse www.advini.com/finance - rubrique Informations Réglementées. A PROPOS D'ADVINI  Fondé en 1872, AdVini est un groupe viticole international, porté par une âme familiale, un actionnariat visionnaire et humaniste et un esprit d'entreprendre.

MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025 Dijon, France le 30 avril 2026 (17h45 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), société pharmaceutique spécialisée en phase avancée de développement et d'enregistrement de ZEPIZURE®, sa solution d'urgence pour la gestion des crises d'épilepsie, annonce avoir mis à la disposition du public et déposé auprès de l'Autorité des Marchés Financiers son rapport financier annuel 2025. Le rapport financier annuel 2025 peut être consulté sur le site internet de la société.

Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over baseline in weeks 9-12 and a 59% median reduction in clinical seizures over baseline in weeks 13-16 New data demonstrate that RAP-219 has a half-life of approximately 22 days RAP-219 was generally well tolerated throughout treatment and follow-up periods BOSTON and SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced results from the follow-up period of its Phase 2a trial of RAP-219 in focal onset seizures (FOS) in a late-breaker podium presentation at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18–22, 2026 in Chicago. In the Phase 2a trial, patients received RAP-219 for 8 weeks and then entered an 8-week follow-up period after treatment ended to evaluate the effect of RAP-219 on long episodes (LEs) – an objective biomarker of epileptiform activity with >90% median concordance with electrographic seizures in this trial – and clinical seizures.

A Paris, le 8 avril 2026 COMMUNIQUE INFORMATION REGLEMENTEE Communiqué précisant les modalités de mise à disposition du Rapport financier annuel 2025 de Crédit Mutuel Home Loan SFH Crédit Mutuel Home Loan SFH informe que ce document est à la disposition du public sur le site de l'émetteur, à l'adresse suivante : https://www.creditmutuel-homeloansfh.eu/en/covered-bonds/documentation/investor-documents.html Ce document est également disponible sur le site de l'AMF. Contact Relations Investisseurs Banque Fédérative du Crédit Mutuel Sandrine Cao Dac Viola :  bfcm-web@creditmutuel.fr Attachment Crédit Mutuel Home Loan SFH - Communiqué de mise à disposition du Rapport financier annuel 2025

LONDON--(BUSINESS WIRE)--Neuphonic and Rapport (a division of Speech Graphics) today announced a partnership to deliver what they believe is among the first fully real-time, photorealistic digital human systems running entirely on standard CPU hardware. The collaboration combines Neuphonic's ultra-low latency text-to-speech technology with Rapport, an interactive AI avatar role play platform powered by production-proven real-time facial and full-body animation technology from Speech Graphics, u.

BOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will present results from its Phase 2a trial of RAP-219 in patients with focal onset seizures (FOS), including new data from the 8-week follow-up period, in a podium presentation at the upcoming 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22 in Chicago.

Ci-joint le rapport financier annuel 2025 Attachment Rapport Financier CRCAM 2025